Detalhe da pesquisa
1.
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Lancet
; 402(10397): 185-195, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37290461
2.
A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer.
Invest New Drugs
; 41(2): 324-332, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36907947
3.
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.
J Clin Oncol
; : JCO2302166, 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38552197